Which company executives are buying and selling shares of Biogen (NASDAQ:BIIB) stock? What is Biogen's Market Cap? Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, February, 2nd. The firm owned 276,975 shares of the biotechnology company’s stock after buying an additional 5,955 shares during the period. There are no changes to Alkermes' existing ratings including the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, Ba3 (LGD3) senior secured rating, or the SGL-1 Speculative Grade Liquidity Rating. … The average number of shares traded each day over the past 30 days, The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks, The ratio of annual dividend to current share price that estimates the dividend return of a stock, A score provided by CDP (formerly the Carbon Disclosure Project) that rates a company on its climate transparency and performance. … Sawtooth Solutions LLC’s holdings in Biogen were worth $1,661,000 as of its most recent SEC filing. The biotechnology company reported $4.58 EPS for the quarter, missing the Zacks' consensus estimate of $4.87 by ($0.29). NASDAQ:BIIB - Biogen Stock Price Target and Predictions. Alliancebernstein L.P. boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. The company inherits 1.8194% risk (volatility on return distribution) over the 30 days horizon. D.A. Alliancebernstein L.P. owned approximately 0.18% of Biogen worth $67,820,000 at the end […] Biogen (NASDAQ: BIIB) does not pay a dividend. Biogen (NASDAQ:BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. The firm had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.80 billion. MUFG Americas Holdings Corp increased its position in Biogen Inc. (NASDAQ:BIIB) by 76.7% in the fourth quarter, HoldingsChannel.com reports. Overview Forecast Earnings Dividend. For my risk tolerance, Biogen is still too much of a gamble. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; FAQ; Consensus Rating: Hold; Consensus Price Target: $306.13; Forecasted Upside: 14.21 %; Number of Analysts: 33; Breakdown: 5 Sell Ratings; 15 Hold Ratings; 13 Buy Ratings; 0 Strong Buy Ratings $ 268.04 As of 01/11/2021 04:55 PM ET +15.5 (6.14%) 1 … M&T Bank Corp lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 5.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, February, 2nd. Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Biogen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals … Biogen had a net margin of 35.63% and a return on equity of … Citi Research analyst Mohit Bansal downgraded Biogen stock (ticker: BIIB) to Sell from Neutral, and set a new target price of $240. Currency in USD, Trade prices are not sourced from all markets. Sawtooth Solutions LLC reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 37.9% during the fourth quarter, HoldingsChannel.com reports. Twin Capital Management Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 2.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange … Rating Action: Moody's assigns Ba3 to Alkermes' term loan; stable outlookGlobal Credit Research - 08 Mar 2021New York, March 08, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). View real-time stock prices and stock quotes for a full financial overview. (NASDAQ: BIIB) Biogen's 52-week high was $363.92, and its 52-week low was $223.25. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock … , Biogen Stock: Why A Key Medicine Could Shoot To Blockbuster Status By 2025. With Biogen stock trading at $266.49 per share, the total value of Biogen stock (market capitalization) is $41.01B. Shares have lost about 1.4% in that time frame, outperforming the S&P 500. Alliancebernstein L.P. owned approximately 0.18% of Biogen … Biogen Inc (BIIB) - Stock, Realtime Charts, Screeners, News, Price Alerts and Many More. Alliancebernstein L.P. boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. Biogen (NASDAQ:BIIB) Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock … By contrast, DOW inherits 0.8185% risk (volatility on return distribution) over the 30 days horizon. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). 41.7% . Veritable L.P. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 12.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. Veritable L.P.’s holdings in Biogen were worth $1,007,000 as of […] The biotechnology company reported $4.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $4.87 by ($0.29). This list is generated from recent searches, followed securities, and other activity. Biogen Dividends FAQ. The U.S. Food and Drug Administration (FDA) will soon decide the fate of the company's investigational Alzheimer's drug. Man sues Hertz over receipt that cleared him of murder. View Biogen Inc. BIIB investment & stock information. Biogen Inc. Common Stock (BIIB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. View real-time stock prices and stock quotes for a full financial overview. … Raymond James analyst Steven Seedhouse downgraded the stock … Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, February 2nd. © 2021 Verizon Media. Stock analysis for Biogen Inc (BIIB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Stock analysis for Biogen Inc (BIIB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Subscribe to Premium to view Fair Value for BIIB. It has been about a month since the last earnings report for Biogen Inc. (BIIB). Davidson & CO. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. BIIB | Complete Biogen Inc. stock news by MarketWatch. No, BIIB has not paid a dividend within the past 12 months. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. The firm owned 6,785 shares of the biotechnology company’s stock after selling 4,149 shares during the quarter. Get the latest Biogen Inc. BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Davidson & CO. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. Biogen (NASDAQ:BIIB) is facing its biggest moment ever. The average Biogen stock price prediction forecasts a potential downside of N/A from the current BIIB share price of $263.57. Does Biogen pay a dividend? Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ: SAGE)-- announced on … Biogen (BIIB) stock price, charts, trades & the US's most popular discussion forums. It is currently -26.77% from its 52-week high and 19.37% from its 52-week low. W e believe that Biogen stock (NASDAQ: BIIB), a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. What is BIIB's earnings growth forecast for 2021-2023? During the quarter, the stock traded for an average price of $279.04 per share. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen Inc Stock Dividend Yield & Dates Add to Watchlist. But if you pay close attention, you might gather that its strong financials could mean … View BIIB's most recent analyst ratings, analyst estimates and price targets at MarketBeat. QQQ 310.88. S&P 500 3,939.34 (+1.04%) The fund owned 2,175 shares of the biotechnology company’s stock … Last year, its … Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. The firm owned 276,975 shares of the biotechnology company’s stock after buying an additional 5,955 shares during the period. Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Valuation. The institutional investor owned 4,629 shares of the biotechnology company’s stock after acquiring an additional 2,010 shares during the period. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. Tecfidera generic competition will worsen in 2021. All rights reserved. With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). Share Price vs. Fair Value. D.A. Is Biogen undervalued compared to its fair value and its price relative to the market? A high-level overview of Biogen Inc. (BIIB) stock. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Find the latest analyst research for Biogen Inc. Common Stock (BIIB) at Nasdaq.com. Biopharmaceutical concern Biogen Inc (NASDAQ:BIIB) is up 7.9% to trade at $291.00 this morning, after the Food and Drug Administration (FDA) extended the review period for Biogen's experimenta... Investors Business Daily - 1 month ago During the quarter, the stock traded for … The difference between the high and low prices over the past day, The difference between the high and low prices over the past 52 weeks. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; FAQ; Consensus Rating: Hold; Consensus Price Target: $304.47; Forecasted Upside: 14.25 %; Number of Analysts: 32; Breakdown: 5 Sell Ratings; 15 Hold Ratings; 12 Buy Ratings; 0 Strong Buy Ratings $ 266.49 As of 03/9/2021 01:00 AM ET -3.52 (-1.30%) 1 … The biotechnology company reported $4.58 earnings per share for the quarter, missing analysts' consensus estimates of $4.87 by $0.29. How much is Biogen's dividend? Biogen (NASDAQ:BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. :) The Oracle of Omaha picked up 648,447 shares of Biogen , allocating 0.08% of the equity portfolio to the holding. Undervalued compared to fair value. Biogen revenue declined rapidly in Q4 2020. With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). The fund owned 2,175 shares of the biotechnology company’s stock after selling 301 shares during the quarter. If you had invested in Biogen stock … The biotechnology company reported $4.58 earnings per share for the quarter, missing the consensus estimate of $4.87 by ($0.29). The biotechnology company reported $4.58 earnings per share for the quarter, missing the Zacks' consensus estimate of … Is Biogen Inc. (NASDAQ:BIIB) Trading At A 43% Discount? The institutional investor owned 4,113 shares of the biotechnology company’s stock after selling 599 shares during the period. DOW 32,297.02. 3 weeks ago | Simply Wall St Jesus Mantas Is The Independent Director of Biogen Inc. (NASDAQ:BIIB) And They Just Picked Up 44% More Shares Biogen (NASDAQ:BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. :) The Oracle of Omaha picked up 648,447 shares of Biogen , allocating 0.08% of the equity portfolio to the holding. MUFG Americas Holdings Corp’s holdings in Biogen were worth $1,133,000 at the end of the most […] View the most recent insider trading activity for BIIB stock at MarketBeat. S&P 500 3,898.81. Analysts Expect Approval. What is Biogen … Biogen had a return on equity of 51.00% and a net margin of 35.63%. (NASDAQ: BIIB) Biogen stock price per share is $266.49 today (as of Mar 9, 2021). Investors who bought shares of Biogen (NASDAQ:BIIB) in 2010 or earlier and held onto them have plenty of reason to smile; Biogen has gained more than 390% since 2010. Shares fell 1.3% to 266.49 on today's stock market. The fund owned 70,440 shares of the biotechnology company’s stock after selling 3,785 shares during the period. BIIB | Complete Biogen Inc. stock news by MarketWatch. The news comes days before the company is scheduled to release further data on a potential Alzheimer’s disease therapy, called donanmeab. Biogen (NASDAQ: BIIB) does not pay a dividend. A controversial Alzheimer's drug that has weighed on Biogen stock this year could ultimately become a major blockbuster within five years, a market research group predicted Tuesday. Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, February 2nd. Rowland & Co. Investment Counsel ADV lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 18.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. BIIB stock … In Japan, Biogen's MS portfolio is co-promoted by Eisai. Biogen's stock is trading at a price-to-earnings (P/E) ratio of 11, which is cheap compared to the Health Care Select Sector SPDR Fund, where the average holding trades at a P/E of 25. Biogen (NASDAQ:BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. What is Biogen's Dividend Payment Date? What predictions are top-rated research analysts making about Biogen (NASDAQ:BIIB)? Veritable L.P. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 12.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. [7] In May 2006, the company announced it would acquire … Veritable L.P.’s holdings in Biogen … The institutional investor owned 4,113 shares of the biotechnology company’s stock after selling 599 shares during the period. What is the 52 week high and low for Biogen (NASDAQ: BIIB)? NASDAQ:BIIB - Biogen Inc (US) | Quote and Chart | Investagrams {{UserNav.UserFreeTrial.IsEligibleForPrimeFreeTrial ? The company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. You can buy Biogen cheaper than Warren Buffett did! Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. The stock, trading at around $280 this week, has traded between $223.25 and $363.92 over the past 52 weeks. Competitors Biogen (NASDAQ:BIIB) Vs. AMGN, GILD, VRTX, REGN, ALXN, and SGEN. You can buy Biogen cheaper than Warren Buffett did! Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997 . NASDAQ:BIIB - Biogen Stock Price Target and Predictions. The business had revenue of $2.85 billion for the quarter, compared to analysts' expectations of $2.80 billion. Find the latest historical data for Biogen Inc. Common Stock (BIIB) at Nasdaq.com. Free forex prices, toplists, indices and lots more. Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Should You Use Biogen's (NASDAQ:BIIB) Statutory Earnings To Analyse It? But Clarivate analysts … Biogen stock has yo-yoed on these news items. The fund owned 786 shares of the biotechnology company’s stock after purchasing an additional 120 shares during the […] Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. D.A. Biogen had a net margin of 35.63% and a return on equity of 51.00%. M&T Bank Corp’s holdings in Biogen … Should you be buying BIIB stock or one of its competitors? Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ: ... For Biogen, a company whose stock is down 17% year to date, it … The biotechnology company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. Back in June, a judge invalidated a patent on … Ownership. GE, AerCap join air leasing businesses in $30 billion deal. Get the latest Biogen Inc. BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Biogen historical daily return volatility represents how much Biogen stock's price daily returns swing around its mean daily price change - it is a statistical measure of its dispersion of returns. Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, February 2nd. View Biogen Inc. BIIB investment & stock information. Back in June, a judge invalidated a patent on Tecfidera, which is the biotech's …